XML 20 R1.htm IDEA: XBRL DOCUMENT v3.26.1
Document and Entity Information - shares
 12 Months Ended
Dec. 31, 2025
Mar. 08, 2026
Document Information [Line Items]    
Document Type 20-F  
Entity Registrant Name BioLineRx Ltd.  
Entity Central Index Key 0001498403  
Document Period End Date Dec. 31, 2025  
Current Fiscal Year End Date --12-31  
Entity Filer Category Non-accelerated Filer  
Amendment Flag false  
Document Registration Statement false  
Document Annual Report true  
Document Transition Report false  
Document Shell Company Report false  
Document Accounting Standard International Financial Reporting Standards  
Document Financial Statement Error Correction [Flag] false  
Entity's Reporting Status Current Yes  
Entity a Voluntary Filer No  
Entity Incorporation State Country Code L3  
Contact Personnel Fax Number 972 (8) 642-9101  
Entity Address, Address Line One 2 HaMa’ayan Street  
Entity Address, City or Town Modi’in  
Entity Address, Postal Zip Code 7177871  
Entity Address, Country IL  
Entity Interactive Data Current Yes  
Document Fiscal Year Focus 2025  
Document Fiscal Period Focus FY  
Entity Common Stock, Shares Outstanding   2,610,814,390
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity File Number 001-35223  
Entity a Well-known Seasoned Issuer No  
ICFR Auditor Attestation Flag false  
Auditor Name Kesselman & Kesselman  
Auditor Location Tel Aviv, Israel  
Auditor Firm ID 1309  
Auditor Opinion [Text Block]
Opinion on the Financial Statements
 
We have audited the accompanying consolidated statements of financial position of BioLineRx Ltd. and its subsidiaries (the “Company”) as of December 31, 2025 and 2024, and the related consolidated statements of comprehensive loss, changes in equity and cash flows for each of the three years in the period ended December 31, 2025, including the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024 and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025 in conformity with IFRS Accounting Standards as issued by the International Accounting Standards Board.
 
Substantial Doubt about the Company’s Ability to Continue as a Going Concern
 
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1(c) to the consolidated financial statements, the Company has suffered recurring losses from operations and has cash outflows from operating activities that indicate that a material uncertainty exists that may cast significant doubt (or raise substantial doubt as contemplated by PCAOB standards) about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1(c). The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
  
Business Contact [Member]    
Document Information [Line Items]    
Contact Personnel Name Philip A. Serlin  
Contact Personnel Email Address phils@biolinerx.com  
Entity Address, Address Line One 2 HaMa’ayan Street  
Entity Address, City or Town Modi’in  
Entity Address, Postal Zip Code 7177871  
City Area Code 972  
Local Phone Number 642-9100  
Entity Address, Country IL